The Trump administration has pledged to curb rising obesity with school meal reforms and artificial dye bans, though the ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

A Plant-Based Formula With Science-Referenced Compounds Designed to Support Hormonal Weight Balance Without Prescription ...

As consumers drop pounds, beauty and wellness brands are dropping products in hopes of cashing in on the rise of weight-loss drugs.

Stocks closed lower Tuesday as investors took a breather from a rally that had pushed major indexes to a series of record ...

PG fell 0.3%, though it was hardly the worst-performing Dow Jones stock today. That honor went to UnitedHealth Group ( UNH ).

With over 40% of Americans classified as obese, the need for effective long-term weight-loss solutions is greater than ever. Obesity can lead to serious health issues like diabetes, heart disease, ...

A major new study has shown that a group of drugs called GLP-1 receptor agonists offer strong protection for both the kidneys ...

We are nearing a point of no return for GLP-1 drugs. More than one in 10 Americans have already taken a GLP-1 agonist, be it ...

Meshel Laurie has got candid about her whopping 60kg weight loss as she called for a controversial obesity medication to be added to the Pharmaceutical Benefits Scheme (PBS).

A YOUNG woman has revealed that in 14 weeks, she has lost three stone on Mounjaro. But although Jess now feels “healthier” ...

Maziar Mike Doustdar takes over at Novo Nordisk as the company reports weaker earnings than expected on generic challenges to its blockbuster weight-loss drug, Wegovy.